Skip to main content

Table 1 The baseline clinical characteristics of enrolled patients with stage IIIA-N2 NSCLC before and after PSM

From: Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database

Clinical parameters

Before PSM

After PSM

Non-PORT

(N = 2535)

PORT

(N = 1446)

P-value

Non-PORT

(N = 1380)

PORT

(N = 1380)

P-value

Age, years (range)

67 (22–90)

64 (19–88)

< 0.001*

65 (22–89)

65 (28–88)

0.674

Sex

  

0.942

  

0.469

Male

1253 (49.43%)

713 (49.31%)

 

669 (48.48%)

688 (49.86%)

 

Female

1282 (50.57%)

733 (50.69%)

 

711 (51.52%)

692 (50.14%)

 

Race

  

0.585

  

0.591

Black

256 (10.10%)

141 (9.75%)

 

152 (11.01%)

136 (9.86%)

 

White

2051 (80.91%)

1161 (80.29%)

 

1091 (79.06%)

1109 (80.36%)

 

Others or unknown

228 (8.99%)

144 (9.96%)

 

137 (9.93%)

135 (9.78%)

 

Year of diagnosis

  

< 0.001*

  

0.360

2004–2009

1370 (54.04%)

645 (44.61%)

 

653 (47.32%)

629 (45.58%)

 

2010–2015

1165 (45.96%)

801 (55.39%)

 

727 (52.68%)

751 (54.42%)

 

Laterality

  

0.154

  

0.378

Right

1373 (54.16%)

817 (56.50%)

 

760 (55.07%)

783 (56.74%)

 

Left

1162 (45.84%)

629 (43.50%)

 

620 (44.93%)

597 (43.26%)

 

Primary site

  

0.021*

  

0.766

Main bronchus

30 (1.18%)

16 (1.11%)

 

18 (1.30%)

15 (1.09%)

 

Upper lobe

1415 (55.82%)

869 (60.10%)

 

793 (57.46%)

822 (59.57%)

 

Middle lobe

113 (4.46%)

74 (5.12%)

 

67 (4.86%)

71 (5.14%)

 

Lower lobe,

911 (35.94%)

463 (32.02%)

 

476 (34.49%)

448 (32.46%)

 

Overlapping lesion of lung

66 (2.60%)

24 (1.66%)

 

26 (1.88%)

24 (1.74%)

 

Tumor size, mm (range)

35 (1–195)

35 (5–180)

0.325

35 (1–190)

34 (5–180)

0.584

Histologic type

  

0.136

  

0.876

Adenocarcinoma

1622 (63.98%)

970 (67.08%)

 

920 (66.67%)

912 (66.09%)

 

Squamous cell carcinoma

597 (23.55%)

307 (21.23%)

 

292 (21.16%)

303 (21.96%)

 

Others

316 (12.47%)

169 (11.69%)

 

168 (12.17%)

165 (11.96%)

 

Grade

  

0.604

  

0.855

Well differentiated

126 (4.97%)

58 (4.01%)

 

64 (4.64%)

55 (3.99%)

 

Moderately differentiated

1062 (41.89%)

603 (41.70%)

 

586 (42.46%)

574 (41.59%)

 

Poorly differentiated

1132 (44.65%)

655 (45.30%)

 

611 (44.28%)

625 (45.29%)

 

Undifferentiated; anaplastic

64 (2.52%)

34 (2.35%)

 

34 (2.46%)

33 (2.39%)

 

Unknown

151 (5.96%)

96 (6.64%)

 

85 (6.16%)

93 (6.74%)

 

Surgical procedure

  

< 0.001*

  

0.239

Lobectomy

2229 (87.93%)

1324 (91.56%)

 

1242 (90.00%)

1260 (91.30%)

 

Pneumonectomy

306 (12.07%)

122 (8.44%)

 

138 (10.00%)

120 (8.70%)

 

T stage (sixth edition)

  

0.075

  

0.122

T1

697 (27.50%)

411 (28.42%)

 

391 (28.33%)

391 (28.33%)

 

T2

1667 (65.76%)

912 (63.07%)

 

899 (65.14%)

871 (63.12%)

 

T3

171 (6.75%)

123 (8.51%)

 

90 (6.52%)

118 (8.55%)

 

LN examined (range)

11 (1–90)

11 (1–79)

0.812

11 (1–90)

11 (1–79)

0.595

Metastatic LN

  

< 0.001*

  

0.644

> 4

630 (24.85%)

450 (31.12%)

 

392 (28.41%)

403 (29.20%)

 

<=4

1905 (75.15%)

996 (68.88%)

 

988 (71.59%)

977 (70.80%)

 

Positive LN ratio (%)

  

< 0.001*

  

0.386

> 50

488 (19.25%)

376 (26.00%)

 

301 (21.81%)

320 (23.19%)

 

<=50

2047 (80.75%)

1070 (74.00%)

 

1079 (78.19%)

1060 (76.81%)

 

Chemotherapy

  

< 0.001*

  

0.673

No

1028 (40.55%)

151 (10.44%)

 

158 (11.45%)

151 (10.94%)

 

Yes

1507 (59.45%)

1295 (89.56%)

 

1222 (88.55%)

1229 (89.06%)

 

Median FU, months (range)

27 (1–154)

28 (1–154)

0.010*

29 (1–154)

28.5 (1–154)

0.852

  1. LN, lymph node; FU, follow-up time; PSM, propensity score-matching; PORT, postoperative radiotherapy
  2. *P < 0.05 was considered significant and marked in bold. Data represent as median (range) or n (%)